Cascadian Therapeutics Inc (CASC):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Cascadian Therapeutics Inc (CASC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10058
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:51
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cascadian Therapeutics Inc (Cascadian), formerly Oncothyreon Inc is a clinical-stage biotechnology company that develops therapeutic products for the treatment of cancer. The company’s lead clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule HER2 inhibitor which is intended for the treatment of HER2-positive (HER2+) metastatic breast cancer. It also develops preclinical product candidates in oncology through its Chk1 kinase inhibitor and protocell technology. The company partners with various pharmaceutical companies to enhance its pipeline of product candidates. Cascadian is headquartered in Seattle, Washington, the US.

Cascadian Therapeutics Inc (CASC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Adimab Enters into Agreement with Oncothyreon 11
Licensing Agreements 12
Oncothyreon Enters into Licensing Agreement with Array BioPharma for ONT-380 12
Sentinel Oncology Enters Into Licensing Agreement With Oncothyreon To Develop Chk1 Inhibitors 13
Braeburn Pharma Enters into Licensing Agreement with Oncothyreon 14
Equity Offering 15
Cascadian Therapeutics Plans to Raise up to USD250 Million in Public Offering of Shares 15
Cascadian Therapeutics Raises USD87.97 million in Public Offering of Shares 16
Cascadian Therapeutics Raises USD6 Million in Public Offering of Series E Preferred Stock 18
Cascadian Therapeutics Raises USD32.2 Million in Public Offering of Shares 20
Cascadian Therapeutics Raises USD13.8 Million in Private Placement of Shares 22
Oncothyreon to Raise up to USD50 Million in Public Offering of Shares 24
Oncothyreon Prices Public Offering of Shares for USD20 Million 25
Oncothyreon Prices Public Offering of Preferred Shares for USD2 Million 27
Oncothyreon Raises USD20 Million in Public Offering of Preferred Shares 29
Oncothyreon Raises USD23 Million in Public Offering of Shares 31
Oncothyreon Raises USD16.6 million Public Offering Of Common Stock 33
Oncothyreon Completes Private Placement Of Units For US$10 Million 34
Oncothyreon Completes Public Offering Of Common Stock For US$54 Million 35
Acquisition 37
Seattle Genetics Acquires Cascadian Therapeutics for USD614 Million in Tender Offer 37
Oncothyreon Acquires Alpine Biosciences for USD27 Million 39
Cascadian Therapeutics Inc – Key Competitors 40
Cascadian Therapeutics Inc – Key Employees 41
Cascadian Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Nov 08, 2017: Cascadian Therapeutics Reports Third Quarter 2017 Financial Results 43
Aug 08, 2017: Cascadian Therapeutics Reports Second Quarter 2017 Financial Results 45
Mar 09, 2017: Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results 46
Corporate Communications 47
Dec 13, 2017: Cascadian Therapeutics Added to the Nasdaq Biotechnology Index 47
Mar 13, 2017: Cascadian Therapeutics Announces Changes to Board of Directors 48
Other Significant Developments 49
Jan 05, 2017: Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress 49
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51

List of Tables
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cascadian Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adimab Enters into Agreement with Oncothyreon 11
Oncothyreon Enters into Licensing Agreement with Array BioPharma for ONT-380 12
Sentinel Oncology Enters Into Licensing Agreement With Oncothyreon To Develop Chk1 Inhibitors 13
Braeburn Pharma Enters into Licensing Agreement with Oncothyreon 14
Cascadian Therapeutics Plans to Raise up to USD250 Million in Public Offering of Shares 15
Cascadian Therapeutics Raises USD87.97 million in Public Offering of Shares 16
Cascadian Therapeutics Raises USD6 Million in Public Offering of Series E Preferred Stock 18
Cascadian Therapeutics Raises USD32.2 Million in Public Offering of Shares 20
Cascadian Therapeutics Raises USD13.8 Million in Private Placement of Shares 22
Oncothyreon to Raise up to USD50 Million in Public Offering of Shares 24
Oncothyreon Prices Public Offering of Shares for USD20 Million 25
Oncothyreon Prices Public Offering of Preferred Shares for USD2 Million 27
Oncothyreon Raises USD20 Million in Public Offering of Preferred Shares 29
Oncothyreon Raises USD23 Million in Public Offering of Shares 31
Oncothyreon Raises USD16.6 million Public Offering Of Common Stock 33
Oncothyreon Completes Private Placement Of Units For US$10 Million 34
Oncothyreon Completes Public Offering Of Common Stock For US$54 Million 35
Seattle Genetics Acquires Cascadian Therapeutics for USD614 Million in Tender Offer 37
Oncothyreon Acquires Alpine Biosciences for USD27 Million 39
Cascadian Therapeutics Inc, Key Competitors 40
Cascadian Therapeutics Inc, Key Employees 41
Cascadian Therapeutics Inc, Subsidiaries 42

List of Figures
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Cascadian Therapeutics Inc (CASC):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • University of Texas Health Science Center at Houston-製薬・医療分野:企業M&A・提携分析
    Summary University of Texas Health Science Center at Houston (UTHealth), a subsidiary of University of Texas System is an educational institution that provides research, education and patient care services. The university operates with schools of biomedical informatics, biomedical sciences, dentistr …
  • Awilco LNG ASA (ALNG):企業の財務・戦略的SWOT分析
    Summary Awilco LNG ASA (Awilco LNG), a subsidiary of Awilhelmsen AS, is an oil and gas company that provides LNG transportation programs. The company owns and operates LNG vessels intended for international trading. It offers LNG value chain such as liquefaction, production, regasification, transpor …
  • ManTech International Corp (MANT):企業の財務・戦略的SWOT分析
    ManTech International Corp (MANT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Pattern Energy Group Inc (PEGI):企業の財務・戦略的SWOT分析
    Pattern Energy Group Inc (PEGI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Genpact Ltd:企業の戦略・SWOT・財務情報
    Genpact Ltd - Strategy, SWOT and Corporate Finance Report Summary Genpact Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Outotec Oyj:企業のM&A・事業提携・投資動向
    Outotec Oyj - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Outotec Oyj Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Kohler Co:企業の戦略的SWOT分析
    Kohler Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • J. Knipper and Company Inc:企業の戦略的SWOT分析
    J. Knipper and Company Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Diamond Offshore Drilling Inc (DOFSQ):企業の財務・戦略的SWOT分析
    Diamond Offshore Drilling Inc (DOFSQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Ensign Energy Services Inc (ESI):石油・ガス:M&Aディール及び事業提携情報
    Summary Ensign Energy Services Inc (Ensign Energy) is an oil and gas company that offers oilfield services. The company’s services include directional drilling, horizontal drilling, well servicing and testing services. It provides well completions and recompletions, abandonment of redundant wells, s …
  • Fuji Electric Co., Ltd.:企業の戦略・SWOT・財務分析
    Fuji Electric Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Fuji Electric Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • TClarke PLC (CTO):企業の財務・戦略的SWOT分析
    TClarke PLC (CTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Mangalore Refinery and Petrochemicals Ltd (MRPL):企業の財務・戦略的SWOT分析
    Mangalore Refinery and Petrochemicals Ltd (MRPL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key s …
  • Bumi Armada Bhd (ARMADA):企業の財務・戦略的SWOT分析
    Bumi Armada Bhd (ARMADA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Temple University-製薬・医療分野:企業M&A・提携分析
    Summary Temple University (Temple) is an educational and research university that offers undergraduate and graduate courses. The university offers undergraduate courses in various fields which include arts, media and communication, medicine, engineering, pharmacy and others. Temple offers its degree …
  • Nan Ya Plastics Corp (1303):企業の財務・戦略的SWOT分析
    Nan Ya Plastics Corp (1303) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • hVIVO Plc (HVO):企業の財務・戦略的SWOT分析
    Summary hVIVO Plc (hVIVO), formerly Retroscreen Virology Ltd is a biopharma company that develops human-based analytical platform to accelerate drug discovery and development. The company enables organisations to discover drugs and diagnostics and accelerate new product development. It uses human di …
  • BioScrip Inc (BIOS):医療機器:M&Aディール及び事業提携情報
    Summary BioScrip Inc (BioScrip), formerly MIM Corp is a healthcare service provider that provides infusion care services. The hospital offers a range of infusion services, PBM services and respiratory services. It provides infusion therapy services such as antimicrobial drugs, factor replacement the …
  • Pousadas de Portugal:企業の戦略・SWOT・財務情報
    Pousadas de Portugal - Strategy, SWOT and Corporate Finance Report Summary Pousadas de Portugal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • CooperVision Inc:製品パイプライン分析
    Summary CooperVision Inc (CooperVision), a subsidiary of The Cooper Companies Inc, designs and manufactures soft contact lenses. It manufactures a wide array of monthly, two-week and daily disposable contact lenses. CooperVision helps overcome various vision challenges such as astigmatism and presby …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆